Patients who have had an ischemic stroke are at risk of having another. Warfarin is the treatment of choice for the prevention of recurrent cardioembolic stroke. In this study, warfarin and aspirin were compared in the prevention of recurrent ischemic stroke due to causes other than cardioembolism. There was no significant difference between the warfarin and aspirin groups in either the rate of recurrence of ischemic stroke or the rate of hemorrhagic complications. In this study, there was no significant difference between the warfarin and aspirin groups in the rate of recurrence of ischemic stroke. Long-standing doubts, expressed as late as the 1980s, about the efficacy of warfarin for the prevention of stroke 1 were mitigated by the results of more recent clinical trials. Recurrence rates were lower with warfarin than with placebo in patients who had stroke after myocardial infarction. 2 The rates of first stroke in patients with atrial fibrillation were lower with warfarin than with a range of other therapies, 3 placebo, 4 or aspirin. 5 Also, in open-label studies, the rates of recurrent stroke were lower with warfarin than with placebo or aspirin. 6 Rates of adverse events with warfarin were acceptably low at the ranges of . . .